Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment extends survival for patients with advanced lung cancer

14.07.2005


Erlotinib increases survival by several months



An international clinical trial led by Canadian researchers has demonstrated that a drug called erlotinib increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options.

The trial, funded by the Canadian Cancer Society and published in tomorrow’s issue of The New England Journal of Medicine, involved 731 patients at centres in North and South America, Europe, Israel, New Zealand, Asia and South Africa. The patients had already received at least one or two regimens of chemotherapy and were randomly assigned to one of two groups: 488 patients received erlotinib and 243 received a placebo. The researchers found that treatment with erlotinib resulted in longer survival compared to the placebo. Patients who received erlotinib survived an average of 6.7 months, while patients on placebo survived an average of 4.7 months – a 42.5 per cent improvement. Of the patients receiving erlotinib, 31 per cent were alive after one year, compared to only 22 per cent of patients receiving placebo. Unlike many chemotherapies, erlotinib was generally well-tolerated and caused only minor side effects.


"This drug offers a new treatment option to patients at a time in their disease when they have no other options," says Dr. Frances Shepherd, the study’s principal investigator, holder of the Scott Taylor Chair in Lung Cancer Research and medical oncologist at Princess Margaret Hospital, and professor of medicine at the University of Toronto. "Not only does erlotinib help them live longer, but it also improves their physical function, their quality of life, and it improves their symptoms of cough, shortness of breath and pain."

Dr. Barbara Whylie, CEO of the Canadian Cancer Society, says, "This is a welcome advance in the treatment of lung cancer, the most common cause of cancer death in Canada. Canadian researchers continue to be at the forefront of new advances in the fight against this disease and we are committed to continuing to support their outstanding efforts."

Also known commercially as Tarceva, erlotinib slows down tumour growth by interfering with a specific cellular pathway that promotes cell division. The drug interferes with epidermal growth factor receptors (EGFR), which receive an ongoing signal for the cells to divide, thus driving the cancer’s growth. Erlotinib specifically targets EGFR to prevent the tumour from growing. This is the first drug of the EGFR inhibitors family demonstrated to improve survival. In November 2004, the U.S. Food and Drug Administration approved erlotinib for patients with advanced non-small cell lung cancer who had received at least one regimen of chemotherapy.

In a companion study, also published in tomorrow’s issue of The New England Journal of Medicine, scientists led by Dr. Ming Tsao and Dr. Frances Shepherd at Princess Margaret Hospital assessed tumour biopsies from some of the patients on the trial. They looked for gene mutations, gene copy number, and the expression of the epidermal growth factor receptor protein in the cancer cells. Their findings suggest that molecular testing is not necessary to identify appropriate patients for treatment with erlotinib.

Lung cancer is one of the most common forms of cancer worldwide, and it is the leading cause of death from cancer in North America. Non-small cell lung cancer is the most common type of lung cancer, accounting for almost 80 per cent of all cases. An estimated 22,200 Canadians will be diagnosed with lung cancer this year, and 19,000 will die of the disease.

The lung cancer clinical trial was coordinated by the National Cancer Institute of Canada Clinical Trials Group, which is funded by the Canadian Cancer Society and based at Queen’s University in Kingston, Ontario. It was also funded by OSI Pharmaceuticals Inc.

Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer. Princess Margaret Hospital is a member of the University Health Network, which also includes Toronto General Hospital and Toronto Western Hospital. All three are teaching hospitals affiliated with the University of Toronto.

Jennifer Kohm | EurekAlert!
Further information:
http://www.cancer.ca
http://www.utoronto.ca

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>